Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $1183

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1163 to $1183.

Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; Does Not Expect Future Milestones Or Royalties Under Agreement After Termination

 Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate that certain

4 Health Care Stocks With Whale Alerts In Today's Session

Amazon GLP-1 Program Pressures Hims & Hers Stock

Hims & Hers stock falls as Amazon launches a weight loss program with integrated care, pricing options, and nationwide delivery.

Amazon One Medical Introduces Weight Management Program With Upfront GLP-1 Medication Costs

https://www.aboutamazon.com/news/retail/amazon-glp1-management-program

Eli Lilly Goes Atomic—But This Isn't About AI Servers

Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power.

Eli Lilly Signs Agreement To Acquire Kelonia Therapeutics For $7B In Cash, Including $3.25B Upfront Payment

Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire

'Eli Lilly Nears Deal for Cancer Biotech' - WSJ

https://www.wsj.com/tech/biotech/eli-lilly-nears-deal-for-cancer-biotech-db07be72 

Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis'

Compass Pathways said a White House executive order may speed FDA review of its psilocybin therapy COMP360 for treatment-resistant depression trials.

Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

On Saturday, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to move faster on reviews tied to psychedelic-based research and treatment, including ibogaine that veteran advocates say may help post-traumatic stress disorder.